U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Lung Hodgkin Lymphoma

MedGen UID:
1789531
•Concept ID:
C2046647
•
Neoplastic Process
Synonyms: Primary Lung Hodgkin Lymphoma; Primary Pulmonary Hodgkin Lymphoma; Pulmonary Hodgkin Lymphoma

Definition

A rare Hodgkin lymphoma that arises in and is confined to the lung at the time of diagnosis. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLung Hodgkin Lymphoma

Professional guidelines

PubMed

HIV-related Malignancies and Mimics: Imaging Findings and Management.
Javadi S, Menias CO, Karbasian N, Shaaban A, Shah K, Osman A, Jensen CT, Lubner MG, Gaballah AH, Elsayes KM
Radiographics 2018 Nov-Dec;38(7):2051-2068. Epub 2018 Oct 19 doi: 10.1148/rg.2018180149. PMID: 30339518

Recent clinical studies

Etiology

Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
Alnimer Y, Ali MKM
Clin Lung Cancer 2022 Dec;23(8):e510-e518. Epub 2022 Aug 7 doi: 10.1016/j.cllc.2022.08.003. PMID: 36008241
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
Lancet Oncol 2018 Feb;19(2):257-266. Epub 2017 Dec 21 doi: 10.1016/S1470-2045(17)30912-9. PMID: 29276022Free PMC Article
Non-AIDS-defining cancers.
Mitsuyasu RT
Top Antivir Med 2014 Jun-Jul;22(3):660-5. PMID: 25101532Free PMC Article
Non-AIDS-defining cancers among HIV-infected people.
Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, Zanghì G, Nunnari G
Eur Rev Med Pharmacol Sci 2012 Oct;16(10):1377-88. PMID: 23104654
Primary pulmonary lymphoma.
Graham BB, Mathisen DJ, Mark EJ, Takvorian RW
Ann Thorac Surg 2005 Oct;80(4):1248-53. doi: 10.1016/j.athoracsur.2005.04.014. PMID: 16181848

Diagnosis

Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
Alnimer Y, Ali MKM
Clin Lung Cancer 2022 Dec;23(8):e510-e518. Epub 2022 Aug 7 doi: 10.1016/j.cllc.2022.08.003. PMID: 36008241
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
Lancet Oncol 2018 Feb;19(2):257-266. Epub 2017 Dec 21 doi: 10.1016/S1470-2045(17)30912-9. PMID: 29276022Free PMC Article
Non-AIDS-defining cancers.
Mitsuyasu RT
Top Antivir Med 2014 Jun-Jul;22(3):660-5. PMID: 25101532Free PMC Article
Human immunodeficiency and Hodgkin lymphoma.
Sissolak G, Sissolak D, Jacobs P
Transfus Apher Sci 2010 Apr;42(2):131-9. doi: 10.1016/j.transci.2010.01.008. PMID: 20138008
Primary pulmonary lymphoma.
Graham BB, Mathisen DJ, Mark EJ, Takvorian RW
Ann Thorac Surg 2005 Oct;80(4):1248-53. doi: 10.1016/j.athoracsur.2005.04.014. PMID: 16181848

Therapy

Penpulimab: First Approval.
Dhillon S
Drugs 2021 Dec;81(18):2159-2166. doi: 10.1007/s40265-021-01640-9. PMID: 34813051
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098
Sintilimab: First Global Approval.
Hoy SM
Drugs 2019 Feb;79(3):341-346. doi: 10.1007/s40265-019-1066-z. PMID: 30742278
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
Lancet Oncol 2018 Feb;19(2):257-266. Epub 2017 Dec 21 doi: 10.1016/S1470-2045(17)30912-9. PMID: 29276022Free PMC Article
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S
Eur J Cancer 2017 Nov;85:67-77. Epub 2017 Sep 9 doi: 10.1016/j.ejca.2017.08.014. PMID: 28892775

Prognosis

Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
Alnimer Y, Ali MKM
Clin Lung Cancer 2022 Dec;23(8):e510-e518. Epub 2022 Aug 7 doi: 10.1016/j.cllc.2022.08.003. PMID: 36008241
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis.
Soteriades ES, Kim J, Christophi CA, Kales SN
Asian Pac J Cancer Prev 2019 Nov 1;20(11):3221-3231. doi: 10.31557/APJCP.2019.20.11.3221. PMID: 31759344Free PMC Article
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
Lancet Oncol 2018 Feb;19(2):257-266. Epub 2017 Dec 21 doi: 10.1016/S1470-2045(17)30912-9. PMID: 29276022Free PMC Article
Cancer statistics, 2013.
Siegel R, Naishadham D, Jemal A
CA Cancer J Clin 2013 Jan;63(1):11-30. Epub 2013 Jan 17 doi: 10.3322/caac.21166. PMID: 23335087
Primary pulmonary lymphoma.
Graham BB, Mathisen DJ, Mark EJ, Takvorian RW
Ann Thorac Surg 2005 Oct;80(4):1248-53. doi: 10.1016/j.athoracsur.2005.04.014. PMID: 16181848

Clinical prediction guides

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963Free PMC Article
Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis.
Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y, Zeng X
Autoimmun Rev 2022 May;21(5):103084. Epub 2022 Mar 24 doi: 10.1016/j.autrev.2022.103084. PMID: 35341972
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
Lancet Oncol 2018 Feb;19(2):257-266. Epub 2017 Dec 21 doi: 10.1016/S1470-2045(17)30912-9. PMID: 29276022Free PMC Article
Eosinophils in Cancer: Favourable or Unfavourable?
Sakkal S, Miller S, Apostolopoulos V, Nurgali K
Curr Med Chem 2016;23(7):650-66. doi: 10.2174/0929867323666160119094313. PMID: 26785997
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F
Lancet Oncol 2015 Jun;16(6):704-15. Epub 2015 Apr 27 doi: 10.1016/S1470-2045(15)70128-2. PMID: 25925619

Recent systematic reviews

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A, Sporis ND, Lazar AL, Buruiana A, Ganea AM, Malinescu TV, Berechet BM, Fodor A, Sitar-Taut AV, Vlad VC, Negrean V, Orasan OH
Int J Mol Sci 2022 Sep 19;23(18) doi: 10.3390/ijms231810948. PMID: 36142866Free PMC Article
Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis.
Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y, Zeng X
Autoimmun Rev 2022 May;21(5):103084. Epub 2022 Mar 24 doi: 10.1016/j.autrev.2022.103084. PMID: 35341972
Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis.
Clarke AE, Pooley N, Marjenberg Z, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER
Semin Arthritis Rheum 2021 Dec;51(6):1230-1241. Epub 2021 Sep 30 doi: 10.1016/j.semarthrit.2021.09.009. PMID: 34710720
Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.
Terret C, Albrand G, Rainfray M, Soubeyran P
Expert Rev Hematol 2015 Jun;8(3):329-41. Epub 2015 Mar 16 doi: 10.1586/17474086.2015.1024650. PMID: 25771832
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.
Lorigan P, Radford J, Howell A, Thatcher N
Lancet Oncol 2005 Oct;6(10):773-9. doi: 10.1016/S1470-2045(05)70387-9. PMID: 16198983

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...